Insulin glulisine is a rapid-acting human insulin analogue produced by recombinant DNA technology using a non-pathogenic laboratory strain of Escherichia coli (K12). It differs from human insulin by the replacement of asparagine at position B3 with lysine and lysine at position B29 with glutamic acid. This modification results in a more rapid onset and shorter duration of action compared to regular human insulin, making it suitable for prandial (mealtime) glucose control in diabetes mellitus. It is typically administered subcutaneously 0-15 minutes before a meal or within 20 minutes after starting a meal.
Adult: Dose is individualized based on metabolic needs, blood glucose monitoring, and glycemic control goal. Typically 0.5 to 1.0 unit/kg/day, divided as prandial doses. The prandial dose is usually 50-70% of the total daily insulin requirement, adjusted per meal carbohydrate content and pre-meal blood glucose. Administer 0-15 minutes before or within 20 minutes after starting a meal.
Note: For subcutaneous use only. Inject into abdominal wall, thigh, upper arm, or buttocks. Rotate injection sites within the same region to reduce lipodystrophy. Use a U-100 insulin syringe or pen device. Do not mix with any other insulin in the same syringe unless specifically indicated (some preparations are approved for mixing with NPH insulin). Do not administer intravenously except under medical supervision for specific conditions like diabetic ketoacidosis (though regular insulin is preferred for IV).
Insulin glulisine binds to the insulin receptor (a transmembrane tyrosine kinase receptor) on target cells (primarily liver, muscle, and adipose tissue). This binding activates the receptor's intrinsic tyrosine kinase activity, initiating a complex intracellular signaling cascade. This leads to the translocation of glucose transporter type 4 (GLUT4) to the cell membrane, facilitating cellular uptake of glucose from the blood. It also promotes glycogen synthesis, inhibits gluconeogenesis and glycogenolysis, and enhances protein and lipid synthesis.
Pregnancy: Pregnancy Category B (US FDA). Considered compatible for use during pregnancy. Insulin requirements may decrease in first trimester and increase significantly in second/third trimesters. Close monitoring of blood glucose is essential. Preferred over oral antidiabetics.
Driving: Hypoglycemia can impair cognitive and motor functions. Patients should check blood glucose before driving and avoid driving if hypoglycemic or if warning signs are present. Keep fast-acting carbohydrates in the vehicle.
| Corticosteroids (e.g., Prednisolone) | Antagonize insulin effect, increasing blood glucose. Dose increase may be needed. | Major |
| Beta-blockers (e.g., Propranolol) | May mask tachycardia of hypoglycemia and impair counter-regulatory response. | Major |
| Thiazide diuretics (e.g., Hydrochlorothiazide) | May cause hyperglycemia, reducing insulin efficacy. | Moderate |
| ACE Inhibitors (e.g., Ramipril) | May enhance insulin sensitivity, increasing hypoglycemia risk. | Moderate |
| Alcohol | Potentiates hypoglycemic effect and impairs gluconeogenesis. Risk of delayed hypoglycemia. | Major |
| Oral Antidiabetic Drugs (e.g., Sulfonylureas like Glimepiride) | Additive hypoglycemic effect. Dose adjustment required. | Major |
| MAO Inhibitors, Anabolic Steroids | Increase hypoglycemic effect. | Moderate |
| Sympathomimetics (e.g., Salbutamol, Epinephrine) | Increase blood glucose, may require insulin dose increase. | Moderate |
Same composition (Insulin Glulisine (100IU)), different brands: